A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19
Latest Information Update: 19 Aug 2025
At a glance
- Drugs COVID-19 vaccine adjuvanted Novavax (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors Novavax
Most Recent Events
- 01 Aug 2025 New trial record